International Journal of Medical Science and Public Health

2018, Vol: 7, Issue: 11

7/11Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to uploaded

« Previous Article

Case Report

Int J Med Sci Public Health. 2014; 3(3): 372-374

doi: 10.5455/ijmsph.2013.251220131

Sugammadex associate persistant bradycardia

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu.

Cited by (5)

Abstract
Sugammadex is a safe selective relaxant binding agent, composed of modified cyclodextrin molecules. It especially has a selectivity for neuromuscular blocking agents (NMBAs) of steroid composition, such as rocuronium and vecuronium. In this paper, we present a case where intravenous (iv) sugammadex has been applied and subsequently persistent bradycardia has developed. A 56-year-old male patient (weight 77 kg, height 163 cm) was scheduled for ureterorenoscopy because of a stone in the upper part of ureter. Preoperative examination showed possible difficult intubation (mallampati 3). There are no known heart diseases and no history of any drug use. The electrocardiography was in normal sinus rhythm, and the blood biochemistry was normal. (WBC: 8.47 K/mm3; Hb: 14.3 g/dL; Na: 135 mEq/L; K: 3.9 mEq/L; BUN: 41 mg/dL; Creatin: 0.69 mg/dL).When the operation ended, We monitored neuromuscular block level with a neuromuscular monitoring device (TOF- Watch S). At the end of the operation, 200 mg sugammadex (Bridion 200 mg/2 mL, MSD) was administered to the patient through iv injection. Approximately 2 minutes following the administration, the patient developed sinusoidal bradycardia (pulse 35 beats/min). We believe that cardiac side effects may be observed following sugammadex administration and that atropine-resistant bradycardia may also develop.

Key words: Sugammadex; Bradycardia; Case Report

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	Print this Article
	How to cite this article
	Citation Tools
	Related Records
	Articles by Murat Bilgi Articles by Abdullah Demirhan Articles by Akcan Akkaya Articles by Umit Yasar Tekelioglu Articles by Hasan Kocoglu
	on Google
	on Google Scholar
	Article Statistics
	Viewed: 3196 Downloaded: 824 Cited: 5

REFERENCES

1. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104 (3):575-81. [DOI via Crossref] [Pubmed]

2. de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30 (9):599-611. [DOI via Crossref] [Pubmed]

3. Tokuwaka J, Takahashi S, Tanaka M. Anaphylaxis after sugammadex administration. Can J Anaesth. 2013;60 (7):733-4. [DOI via Crossref] [Pubmed]

4. Ohshita N, Tsutsumi YM, Kasai A, Soga T, Kanamura T, Katayama T, et al. Two cases of anaphylactoid reaction after administration of sugammadex. [Article in Japanese]. Masui. 2012;61(11):1261-4. [Pubmed]

5. Osaka Y, Shimada N, Satou M, Masuda T, Ando T, Kozono Y, et al. A case of atrioventricular block (Wenckebach type) induced by sugammadex. JAnesth. 2012;26 (4):627-8. [DOI via Crossref] [Pubmed]

6. Butterworth JF, Mackey DC, Wasnick JD, Morgan GE,Mikhail MS. Morgan & Mikhail's clinical anesthesiology. 5thed. New York: McGraw-Hill Medical Publishing. 2013.

7. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104 (3):569-74. [DOI via Crossref] [Pubmed]

8. Booij LH, van Egmond J, Driessen JJ, de Boer HD. In vivo animal studies with sugammadex. Anaesthesia. 2009;64 (1):38-44. [DOI via Crossref] [Pubmed]

9. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006;96 (1):36-43. [DOI via Crossref] [Pubmed]

10. Kokki M, Ali M, Turunen M, Kokki H. Suspected unexpected adverse effect of sugammadex: hypotension. Eur J Clin Pharmacol. 2012;68 (5):899-900. [DOI via Crossref] [Pubmed]

11. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107(2):239-44. [DOI via Crossref] [Pubmed]

12. Puhringer FK, Rex C, Sielenkamper AW, Claudius C, Larsen PB, Prins ME, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109(2):188-97. [DOI via Crossref] [Pubmed]

13. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104(3):555-62. [DOI via Crossref] [Pubmed]

This Article Cited By the following articles

Sugammadex: Efficacy and Practicality in the Dental Office Anesthesia Progress 2018; 65(2): 113.	1

Sugammadex-induced bradycardia and asystole: how great is the risk? British Journal of Anaesthesia 2018; 121(1): 8.	2

Bradycardia in a Pediatric Heart Transplant Recipient: Is It the Sugammadex? The Journal of Pediatric Pharmacology and Therapeutics 2017; 22(5): 378.	3

Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials Journal of Clinical Anesthesia 2016; 35(): 1.	4

Sugammadex: watch out for new side effects Korean J Anesthesiol 2016; 69(5): 427.	5

How to Cite this Article

Pubmed Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. Sugammadex associate persistant bradycardia. Int J Med Sci Public Health. 2014; 3(3): 372-374. doi:10.5455/ijmsph.2013.251220131

Web Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. Sugammadex associate persistant bradycardia. http://www.ijmsph.com/?mno=48110 [Access: November 21, 2018]. doi:10.5455/ijmsph.2013.251220131

AMA (American Medical Association) Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. Sugammadex associate persistant bradycardia. Int J Med Sci Public Health. 2014; 3(3): 372-374. doi:10.5455/ijmsph.2013.251220131

Vancouver/ICMJE Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. Sugammadex associate persistant bradycardia. Int J Med Sci Public Health. (2014), [cited November 21, 2018]; 3(3): 372-374. doi:10.5455/ijmsph.2013.251220131

Harvard Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu (2014) Sugammadex associate persistant bradycardia. Int J Med Sci Public Health, 3 (3), 372-374. doi:10.5455/ijmsph.2013.251220131

Turabian Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. 2014. Sugammadex associate persistant bradycardia. International Journal of Medical Science and Public Health, 3 (3), 372-374. doi:10.5455/ijmsph.2013.251220131

Chicago Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. "Sugammadex associate persistant bradycardia." International Journal of Medical Science and Public Health 3 (2014), 372-374. doi:10.5455/ijmsph.2013.251220131

MLA (The Modern Language Association) Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu. "Sugammadex associate persistant bradycardia." International Journal of Medical Science and Public Health 3.3 (2014), 372-374. Print. doi:10.5455/ijmsph.2013.251220131

APA (American Psychological Association) Style

Murat Bilgi, Abdullah Demirhan, Akcan Akkaya, Umit Yasar Tekelioglu, Hasan Kocoglu (2014) Sugammadex associate persistant bradycardia. International Journal of Medical Science and Public Health, 3 (3), 372-374. doi:10.5455/ijmsph.2013.251220131



Copyright � 2018 International Journal of Medical Science and Public Health All Rights Reserved. Subject to change without notice from or liability to International Journal of Medical Science and Public Health . For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher Dipika Charan 404, Ridhi Tower, Jodhpur, INDIA 342005 publishernjppp@gmail.com Editorial query editorijmsph1@gmail.com 91-9825219196 91-878-0040272

Contact Information